Replies to post #67956 on Biotech Values

[DewDiligence]

GSK had an HCV polymerase inhibitor in phase-1 that was dropped in 2007.

>Wonder if they would buy vrtx?<

The $57M GSK is paying to get GNLB is barely more than round-off error.

GSK recently discontinued its share-buyback program to facilitate the financing of one or more large acquisitions.